Review of risedronate in the treatment of osteoporosis

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 12, 2001, Pages 2011-2025

  Geusens, P ^a   McClung, M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone; Glucocorticoid induced osteoporosis; Postmenopausal osteoporosis; Risedronate

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; CROSPOVIDONE; ETIDRONIC ACID; FLUORIDE; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; MACROGOL; MAGNESIUM STEARATE; MICROCRYSTALLINE CELLULOSE; NONSTEROID ANTIINFLAMMATORY AGENT; PARATHYROID HORMONE; PLACEBO; PYRIDINYL BISPHOSPHONIC ACID; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SILICON DIOXIDE; TITANIUM DIOXIDE; UNCLASSIFIED DRUG; VITAMIN D;

ACUTE PHASE RESPONSE; ANAMNESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERALIZATION; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERANCE; DRUG USE; ENDOSCOPY; FEMALE; GASTROINTESTINAL DISEASE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; QUALITY OF LIFE; RAT; RISK ASSESSMENT; RISK FACTOR; SPINE; UPPER GASTROINTESTINAL TRACT; VERTEBRA FRACTURE;

EID: 0035195216     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.12.2011     Document Type: Article

References (106)

1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis
2. An update on the diagnosis and assessment of osteoporosis with densitometry
3. Perspective. How many women have osteoporosis?
4. Therapeutic approaches to bone diseases
5. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
6. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy
7. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis
8. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
9. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
10. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
11. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial
12. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
13. Treatment with alendronate prevents fractures in women at highest risk: Results from the Fracture Intervention Trial
14. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures
15. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis
16. Risedronate: A clinical review
17. Risedronate: A review of its pharmacological properties and clinical use in resorptive bone disease
18. Risedronate
19. Bisphosphonates: From the laboratory to the clinic and back again
20. Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats
21. Bisphosphonates: Structure-activity relationships and therapeutic implications
22. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships
23. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages
24. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
25. Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats
26. Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats
27. Skeletal effects of constant and terminated use of risedronate on cortical bone in ovariectomized rats
28. Direct stereological estimation of three-dimensional connectivity in rat vertebrae: Effect of estrogen, etidronate and risedronate following ovariectomy
29. Maintaining restored bone with bisphosphonate in the ovariectomized rat skeleton: Dynamic histomorphometry of changes in bone mass
30. The effects of risedronate on canine cancellous bone remodeling: Three-dimensional kinetic reconstruction of the remodeling site
31. Effects of topical administration of a bisphosphonate (risedronate) on orthodontic tooth movements in rats
32. Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats
33. Inhibitory effect of the topical administration of a bisphosphonate (risedronate) on root resorption incident to orthodontic tooth movement in rats
34. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases
35. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice
36. Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system
37. Bisphosphonates: Mechanisms of action
38. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
39. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships
40. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates
41. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates
42. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway
43. The intracellular target for the antiresorptive aminobisphosphonate drugs in dictyostelium discoideum is the enzyme farnesyl diphosphate synthase
44. Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298
45. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
46. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
47. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase
48. Mechanisms of action of etidronate and other bisphosphonates
49. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
50. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
51. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study
52. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial
53. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy
54. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma
55. Beneficial effects of risedronate in corticosteroid-treated patients: Histology and histomorphometry
56. Alendronate increases bone strength by increasing the mean degree of mineralisation of bone tissue in osteoporotic women
57. Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers
58. The effect of dosing regimen on the pharmacokinetics of risedronate
59. Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration
60. Effect of renal function on risedronate pharmacokinetics after a single oral dose
61. Risedronate gastrointestinal absorption is independent of site and rate of administration
62. Evaluation of the effects of risedronate on hepatic microsomal drug metabolising enzyme activities following administration to rats for 14 days: Lack of an induction response
63. Risk factors for hip fracture in white women
64. Risk of new vertebral fracture in the year following a fracture
65. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study
66. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
67. Hip fracture prediction in elderly men and women: Validation in the Rotterdam study
68. Biomechanics of fractures
69. Falls in older patients: Causes and interventions
70. The effect of exercise on falls in elderly patients
71. A multifactorial intervention to reduce the risk of falling among elderly people in the community
72. Reducing frailty and falls in older persons: An investigation of Tai Chi and computerized balance training
73. Effect of external hip protectors on hip fractures
74. Prevention of hip fracture in elderly people with use of a hip protector
75. Evidence-based management of patients with osteoporosis
76. 3 and calcium to prevent hip fractures in the elderly women
77. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial
78. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: The FAVO study
79. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
80. Treatment of postmenopausal osteoporosis with transdermal estrogen
81. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
82. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study
83. Effect of risedronate on the risk of hip fracture in elderly women
84. Sustained fracture benefit with five years of risedronate in postmenopausal women
85. Sustained effect of Risedronate in the prevention of the first vertebral fracture in women
86. Use of oral corticosteroids and risk of fractures
87. Corticosteroids and fractures: A close encounter of the third cell kind
88. The role of vitamin D in corticosteroid-induced osteoporosis: A meta-analytic approach
89. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss
90. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
91. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial
92. Risedronate 35 mg once a week is as effective as 5 mg daily in postmenopausal women
93. Risedronate treatment does not increase microdamage in the canine femoral neck
94. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles
95. Risedronate, a highly effective, short-term oral treatment for Paget's disease: A dose-response study
96. Improvement of pagetic bone lesions with risedronate treatment: A radiologic study
97. Comparative study of potential for bisphosphonates to damage gastric mucosa of rats
98. Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa
99. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation
100. Esophageal irritation due to alendronate sodium tablets: Possible mechanisms
101. Esophagitis associated with the use of alendronate
102. Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects
103. Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women
104. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae
105. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women
106. Gastroenterologists and choosing the right bisphosphonate